DMD Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on March 10, 2008; DOI: 10.1124/dmd.107.019075


0090-9556/08/3607-1202-1205$20.00
DMD 36:1202-1205, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.019075v1
36/7/1202    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitamura, S.
Right arrow Articles by Ohta, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitamura, S.
Right arrow Articles by Ohta, S.
SHORT COMMUNICATION

Aldehyde Oxidase-Catalyzed Metabolism of N1-Methylnicotinamide in Vivo and in Vitro in Chimeric Mice with Humanized Liver

Shigeyuki Kitamura, Kayoko Nitta, Yoshitaka Tayama, Chiaki Tanoue, Kazumi Sugihara, Tae Inoue, Toru Horie, and Shigeru Ohta

Graduate School of Biomedical Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan (S.K., K.N., Y.T., C.T., K.S., S.O.); PhoenixBio Co., Ltd., Higashihiroshima, Japan (T.I., T.H.); and Nihon Pharmaceutical University, Inamachi, Saitama, Japan (S.K.)

Aldehyde oxidase-mediated oxidation of N1-methylnicotinamide to N1-methyl-2-pyridine-5-carboxamide (2-PY) and N1-methyl-4-pyridone-5-carboxamide (4-PY) in chimeric mice constructed by transplanting human hepatocytes into urokinase-type plasminogen activator-transgenic severe combined immunodeficient mice was examined in vivo and in vitro. The activity in liver cytosol of chimeric mice with a high replacement index was approximately 4-fold higher than that in control mice. Furthermore, the oxidation products in control mice were 2-PY and 4-PY, whereas, in chimeric mice, the major product was 2-PY, as in humans. The aldehyde oxidase in chimeric mouse liver was confirmed to be of human type by immunoblotting analysis. The ratio of pyridones (2-PY/4-PY) excreted in the urine of chimeric mice was closer to that of humans than to that of control mice. Thus, the aldehyde oxidase in chimeric mice has human-type functional characteristics.


Address correspondence to: Dr. Shigeyuki Kitamura, Graduate School of Biomedical Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan. E-mail: skitamu{at}hiroshima-u.ac.jp




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
T. Inoue, K. Nitta, K. Sugihara, T. Horie, S. Kitamura, and S. Ohta
CYP2C9-Catalyzed Metabolism of S-Warfarin to 7-Hydroxywarfarin in Vivo and in Vitro in Chimeric Mice with Humanized Liver
Drug Metab. Dispos., December 1, 2008; 36(12): 2429 - 2433.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.